Skip to main content
      How Do You Measure Success When It Comes to SLE? by Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021

      https://t.co/aVKY4B9CfW h

      Dr. John Cush RheumNow

      4 years 5 months ago
      How Do You Measure Success When It Comes to SLE? by Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021 https://t.co/aVKY4B9CfW https://t.co/ffruCDouaE
      RT @RichardPAConway: Dr Hellgren on pregnancy outcomes in RA 📈disease activity assoc preterm birth and small gestatio

      Richard Conway RichardPAConway

      4 years 5 months ago
      Dr Hellgren on pregnancy outcomes in RA 📈disease activity assoc preterm birth and small gestational age. Low disease activity = no increased risk compared controls @RheumNow #EULAR2021 Abstr#OP0210 https://t.co/L26xWhIFv6
      Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021

      https://t.co/fbi3Kbd2GS https:

      Dr. John Cush RheumNow

      4 years 5 months ago
      Q-DAPSA for Measuring Disease Activity in PsA by Dr. Rachel Tate ( @uptoTate) #EULAR2021 https://t.co/fbi3Kbd2GS https://t.co/afRnle1EJK
      RT @AurelieRheumo: DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl
      Gu

      Aurelie Najm AurelieRheumo

      4 years 5 months ago
      DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl Guselkumab modulates genes expr towards normalization of immune cell composition. Would be interesting to look at STissue signatures too 🧐 @StefanSiebert1 #POS0195 @Rheumnow #EULAR2021 https://t.co/7WChCP3U6W
      RT @ejdein1: #EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extensio

      Eric Dein ejdein1

      4 years 5 months ago
      #EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.
      RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed
      RT @Yuz6Yusof: Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results fro

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years 5 months ago
      Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results from Phase III COSMOS. 44.4% of GUS-treated vs 19.8% Placebo-tx achieved ACR20 response at Wk24 (p<0.001). Well tolerated and No major safety #EULAR2021 #OP0230 @RheumNow https://t.co/EuGaacSuxF
      RT @RichardPAConway: Zara Izadi presents @rheum_covid data on machine learning algorithms to predict ARDS in RMD patient

      Richard Conway RichardPAConway

      4 years 5 months ago
      Zara Izadi presents @rheum_covid data on machine learning algorithms to predict ARDS in RMD patients with COVID. Gradient boosting machine had 81% sensitivity to predict ARDS from baseline data @RheumNow #EULAR2021 Abstr#OP0288 https://t.co/tHlPzeX9He
      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb,

      Dr. John Cush RheumNow

      4 years 5 months ago

      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its faculty.

      RT @Stiddyo: #OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16week

      Paul Studenic Stiddyo

      4 years 5 months ago
      #OP0227 #TYK2 inhibitor deucravacitinib showed good efficacy in #PsA patients vs. placebo in phase 2 16weeks Primary endpoint ACR20 12mg: 62.7% 6mg: 52.9% PLC: 31.8% + well tolarated: no serious adverse events #EULAR2021 @RheumNow https://t.co/6SFqWd79db
      RT @uptoTate: Prospective analysis #OP0220 showed that PsA pt age, dz duration and activity level at tx initiation have

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Prospective analysis #OP0220 showed that PsA pt age, dz duration and activity level at tx initiation have ⬇️ with TNFi over the past 20 years. TNFi retention rates have ⬇️ while remission rates have ⬆️ (notably those in 1st yr tx) #EULAR2021 @RheumNow https://t.co/gnKRfvbHPQ https://t.co/PRunGIxMwx
      RT @doctorRBC: IL-17i expressed in overuse tendinopathy. Secukinumab for tx of rotator cuff tendinopathy?
      ⭐️Phase II

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      IL-17i expressed in overuse tendinopathy. Secukinumab for tx of rotator cuff tendinopathy? ⭐️Phase II study - no difference in rotator cuff score (WORC) vs placebo ⭐️no difference in pain score Abs#POS0022 #EULAR2021 @RheumNow
      ×